bevacizumab,olaparib
astrazeneca,merck,roche
['gyn', 'bevacizumab', 'ovarian', 'paola-1', 'olaparib']
the final analysis of the paola-1/engot-ov25 trial confirmed the benefit of olaparib plus bevacizumab as maintenance therapy following frontline treatment in women with hrd-positive advanced ovarian cancer. #gyncsm #esmo22 | 
Home of the journal ONCOLOGY®, CancerNetwork® offers different perspectives on oncology/hematology through review articles, news, podcasts, blogs, and more.